BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

...unnecessary risks. Does that concern you too?Caplan: Yes...
...this purpose, is necessary but not sufficient?Caplan: Yes...
...collaboration could change the drug development landscape?Caplan: Yes...
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview

...do a full development program? [00:07:49] Paul Stoffels: We think that would be the case, yes...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

...than in past years? [00:15:28] Simone Fishburn: Yes...
...Simone Fishburn: That's worldwide? [00:16:01] Jeff Cranmer: Yes...
BioCentury | Dec 18, 2020
Product Development

Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

...stone to that final destination.[00:08:00] Lauren Martz: Yes...
...into a normal world. [00:22:52] Lauren Martz: Yes...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...Guanylate cyclase 2D membrane retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated...
BioCentury | Dec 12, 2020
Regulation

As U.S. joins U.K., Canada in authorizing BNT162b2 for COVID-19, all eyes turn to deployment

...California San Diego School of Medicine, voted “yes.”...
BioCentury | Dec 11, 2020
Product Development

Pfizer-BioNTech COVID-19 vaccine endorsed at shambolic advisory committee meeting

...California San Diego School of Medicine, voted “yes.”...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

...be some change we've seen there, would you rather take an mRNA one at 90%, yes...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

...looks like?[00:17:42] Mene Pangalos: Yes now that's a great question, I think the answer is yes...
BioCentury | Nov 7, 2020
Politics, Policy & Law

Where China’s Hatch-Waxman Act falls short: a BioCentury podcast

...giving us a big picture view of what those new provisions are? [00:00:48] Tony Chen: Yes...
...measures in China apply to both biologics and to small molecule drugs? [00:06:43] Tony Chen: Yes...
...patent cliff in China. Can you walk us through your thinking there? [00:08:40] Tony Chen: Yes...
Items per page:
1 - 10 of 402